EFFECTS OF THE 5-HT1A PARTIAL AGONISTS GEPIRONE, IPSAPIRONE AND BUSPIRONE ON LOCAL CEREBRAL GLUCOSE-UTILIZATION IN THE CONSCIOUS RAT

被引:16
作者
GRASBY, PM
SHARP, T
ALLEN, T
KELLY, PAT
GRAHAMESMITH, DG
机构
[1] WESTERN GEN INFIRM,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,SCOTLAND
[2] UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND
关键词
GEPIRONE; BUSPIRONE; IPSAPIRONE; GLUCOSE UTILIZATION; HIPPOCAMPUS; LATERAL HABENULAR NUCLEUS;
D O I
10.1007/BF02253595
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The azospirones gepirone (10 mg/kg), ipsapirone (10 mg/kg) and buspirone (10 mg/kg) were examined for their effect on regional cerebral glucose utilization in conscious rats using quantitative 2-deoxyglucose autoradiography. All three 5-HT1A partial agonists reduced glucose utilization in the hippocampus and dentate gyrus by 20-25% and increased glucose utilization by 38-65% in the lateral habenular nucleus; an important relay between striatal/limbic areas and the mid-brain raphe nuclei. The findings emphasize the potential importance of the hippocampus as a site of action for 5-HT1A receptor active drugs in vivo and also suggest that functional activity in the striatal/limbic-habenular-raphe pathway may be influenced by gepirone, ipsapirone and buspirone.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 32 条
[1]  
AGHAJANIAN GK, 1988, SEROTONIN RECEPTORS, P225
[2]   BLOCKADE OF ALPHA-2-ADRENOCEPTORS BY 1-(2-PYRIMIDINYL)-PIPERAZINE (PMP) INVIVO AND ITS RELATION TO THE ACTIVITY OF BUSPIRONE [J].
BIANCHI, G ;
GARATTINI, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 147 (03) :343-350
[3]   1-(2-PYRIMIDINYL)-PIPERAZINE AS ACTIVE METABOLITE OF BUSPIRONE IN MAN AND RAT [J].
CACCIA, S ;
CONTI, I ;
VIGANO, G ;
GARATTINI, S .
PHARMACOLOGY, 1986, 33 (01) :46-51
[4]  
Dourish C.T., 1987, BRAIN 5 HT1A RECEPTO, P261
[5]   ANTAGONIST PROPERTIES OF 1-(2-PYRIMIDINYL)PIPERAZINE AT PRESYNAPTIC ALPHA-2-ADRENOCEPTORS IN THE RAT-BRAIN [J].
GOBBI, M ;
FRITTOLI, E ;
MENNINI, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 180 (01) :183-186
[6]  
GRASBY P M, 1989, Society for Neuroscience Abstracts, V15, P421
[7]  
GRASBY PM, 1990, BRIT J PHARMACOL, V99, pP27
[8]  
Gray J.A., 1987, NEUROPSYCHOLOGY ANXI
[9]  
HAMON M, 1988, J PHARMACOL EXP THER, V248, P1222
[10]  
HOWELL DC, 1989, FUNDAMENTAL STATISTI